Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis
Gösta Holmgren(Umeå University), Mark B. Pepys(Hammersmith Hospital), Oluf Andersen(Sahlgrenska University Hospital), Ole B. Suhr(Umeå University), Bo‐Göran Ericzon(Integrated Cardio Metabolic Centre), B. Gunnar Wallin(Sahlgrenska University Hospital), Andrew W. Seymour(Hammersmith Hospital), Lars Steen(Umeå University), C. G. Groth(Integrated Cardio Metabolic Centre), Sylvia Richardson(Hammersmith Hospital), Philip N. Hawkins(The Royal Free Hospital)
Cited by 581
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k